These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 23196275)
21. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957 [TBL] [Abstract][Full Text] [Related]
22. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer. Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433 [TBL] [Abstract][Full Text] [Related]
23. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods. Zwaenepoel K; Van Dongen A; Lambin S; Weyn C; Pauwels P Histopathology; 2014 Oct; 65(4):539-48. PubMed ID: 24621075 [TBL] [Abstract][Full Text] [Related]
24. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156 [TBL] [Abstract][Full Text] [Related]
25. [ALK fusion gene assessment by fully automatic immunohistochemistry in non-small cell lung cancer]. Guo L; Liu X; Qiu T; Ling Y; Shan L; Xie Y Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):95-8. PubMed ID: 24742568 [TBL] [Abstract][Full Text] [Related]
26. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018 [TBL] [Abstract][Full Text] [Related]
28. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry. Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369 [TBL] [Abstract][Full Text] [Related]
29. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics]. Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670 [TBL] [Abstract][Full Text] [Related]
30. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802 [TBL] [Abstract][Full Text] [Related]
31. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization. Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706 [TBL] [Abstract][Full Text] [Related]
32. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. Wynes MW; Sholl LM; Dietel M; Schuuring E; Tsao MS; Yatabe Y; Tubbs RR; Hirsch FR J Thorac Oncol; 2014 May; 9(5):631-8. PubMed ID: 24722153 [TBL] [Abstract][Full Text] [Related]
33. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. Taheri D; Zahavi DJ; Del Carmen Rodriguez M; Meliti A; Rezaee N; Yonescu R; Ricardo BF; Dolatkhah S; Ning Y; Bishop JA; Netto GJ; Sharma R Virchows Arch; 2016 Sep; 469(3):345-50. PubMed ID: 27271275 [TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958 [TBL] [Abstract][Full Text] [Related]
35. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300 [TBL] [Abstract][Full Text] [Related]
36. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067 [TBL] [Abstract][Full Text] [Related]
37. A comparative analysis of immunohistochemistry and fluorescent Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679 [TBL] [Abstract][Full Text] [Related]
38. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. Tantraworasin A; Lertprasertsuke N; Kongkarnka S; Euathrongchit J; Wannasopha Y; Saeteng S Asian Pac J Cancer Prev; 2014; 15(7):3057-63. PubMed ID: 24815447 [TBL] [Abstract][Full Text] [Related]
39. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]